Multinational biopharma company Celgene chose Boudry in the Canton of Neuchâtel for its international headquarters in 2005. The company has been growing in the canton ever since, and recently disclosed the plans for its new campus in Couvet. The new site will comprise four buildings (production, packaging, storage, reception area) on a total surface area of 37,000 square meters and should be operational as of 2019. “Celgene has high ambitions for the coming years, and expects to double its turnover to 20 billion dollars by 2020”, Vice President of International Technical Operations Michael Morrissey told arcinfo.ch.
Fast-growing Celgene develops products for the treatment of cancer and other severe, immune, inflammatory conditions. The new Couvet site will initially manufacture two products: Otezla, a drug against psoriasis with huge sales potential, and Imnovid, which is used to treat multiple myeloma, a rare form of plasma cancer.
The company currently has 650 employees in the Canton of Neuchâtel (570 in Boudry and 80 in Marin) and about 6,000 worldwide. The new Couvet site is expected to create 100 jobs.